MicroRNA-122 protects against ischemic stroke by targeting Maf1

MENGMENG WANG\textsuperscript{1}, XIAOMAN LIU\textsuperscript{1}, YU WU\textsuperscript{2}, YI WANG\textsuperscript{3}, JIAHUI CUI\textsuperscript{1}, JING SUN\textsuperscript{3}, YING BAI\textsuperscript{1} and MING-FEI LANG\textsuperscript{2}

\textsuperscript{1}Department of Neurology, Affiliated Xinhua Hospital of Dalian University, Dalian, Liaoning 116021; \textsuperscript{2}Medical College and \textsuperscript{3}College of Environmental and Chemical Engineering, Institute of Microanalysis, Dalian University, Dalian, Liaoning 116622, P.R. China

Received March 7, 2020; Accepted September 11, 2020

DOI: 10.3892/etm.2021.10048

Abstract. The protection of brain tissue against damage and the reduction of infarct size is crucial for improving patient prognosis following ischemic stroke. Therefore, the present study aimed to investigate the regulatory effect of microRNA (miR)-122 and its target gene repressor of RNA polymerase III transcription MAF1 homolog (Maf1) on the infarct area in ischemic stroke. Reverse transcription-quantitative PCR (RT-qPCR) was performed to determine miR-122 expression levels in an ischemic stroke [middle cerebral artery occlusion (MCAO)] mouse model. Nissl staining was conducted to measure the infarct area of the MCAO mouse model. Moreover, RT-qPCR was performed to investigate the relationship between the expression of Maf1 and miR-122 in the MCAO mouse model. Dual-luciferase reporter assay in vitro and miR-122 mimic or inhibitor treatment in vivo were conducted to verify that miR-122 targeted and inhibited Maf1 expression. The results suggested that miR-122 was upregulated in the brain tissue of MCAO model mice. miR-122 overexpression effectively reduced the size of the infarct area in comparison with a control and miR-122 knockdown in brain tissue resulted in the opposite effect. Moreover, Maf1 was confirmed to be a direct target of miR-122. The results of a dual-luciferase reporter assay indicated that miR-122 bound to the 3'-untranslated region of Maf1. Maf1 expression decreased after stroke model induction in comparison with that in sham animals, and Maf1 expression was negatively associated with the expression of miR-122. In addition, miR-122 knockdown increased Maf1 expression levels, whereas miR-122 overexpression decreased Maf1 expression levels in comparison with a control. In conclusion, the results suggested that miR-122 improved the outcome of acute ischemic stroke by reducing the expression of Maf1.

Introduction

Stroke is the second largest cause of death worldwide (1,2). The current treatment strategies for ischemic stroke are limited and early reperfusion is primarily established by intravenous thrombolysis or mechanical thrombectomy. However, there are no effective clinical drugs that improve patient prognosis following cerebral tissue infarction (3,4).

MicroRNAs (miRNAs/miRs) are a class of non-coding RNAs that control the translation of the target protein through inhibition of the 3'-untranslated region (UTR) of the target gene (5-7). It has been reported that >33% of human genes are regulated by miRNAs (6). Previous studies have demonstrated that miRNAs are physiologically and pathologically involved in ischemic stroke (7,8). Among them, miR-122 has been reported to be associated with ischemic stroke. miR-122 is encapsulated in exosomes and secreted into body fluids, where it is stable in serum and may serve as a promising biomarker for ischemic stroke (9,10). miR-122 protects against amyloid-β-induced neuronal injury (11); however, the molecular mechanism underlying miR-122-mediated protection against loss of brain function is not completely understood.

It was initially determined that repressor of RNA polymerase III transcription MAF1 homolog (Maf1) was highly expressed in brain tissue with an abundance identified in the hippocampus and cortex (12). Subsequently TORC1 in the mTOR pathway was revealed to be involved in the phosphorylation of Maf1, which led to Maf1 inactivation (13). Since mTOR protects brain tissues from ischemic injuries, downregulation of Maf1 may have an inhibitory effect on the development of ischemic brain injuries (14,15). In addition, H$_2$O$_2$ is produced by brain tissue after ischemic stroke, which can reduce cell function and further aggravate brain injury (16). H$_2$O$_2$ can serve as a messenger and promote the synthesis of the transcription factor Maf1 (17,18). Therefore, it was hypothesized that Maf1 may serve an important role in the development and progression of ischemic stroke; however, the biological
function of Maf1 and its relationship with ischemic stroke are not completely understood.

miR-122 may serve as a potential therapeutic target for ischemic stroke (19), whereas Maf1 may aggravate ischemic stroke, but the specific underlying mechanism is not completely understood (20-23). Therefore, it was hypothesized that miR-122 may be involved in the development of ischemic stroke by targeting Maf1. The present study aimed to investigate the relationship between Maf1 and miR-122 in the development and progression of ischemic stroke.

Materials and methods

Experimental animals. A total of 60 female C57BL/6 mice (age, 6-8 weeks; weight, 20-25 g) were purchased from the Experimental Animal Center of Dalian Medical University. The animals were housed at 23±2°C with 55±5% humidity under a 12-h light/dark cycle with free access to food and water. The present study was approved by the Animal Care Committee of the Xinhua Hospital affiliated to Dalian University and performed in accordance with the National Institutes of Health Guidelines (no. 85-23; revised 1996) for the Care and Use of Laboratory Animals (24).

Lateral ventricle injection. Mice were randomly divided into six groups (n=6 per group) for two experimental studies: The effect of miR-122 on infarct size after stroke (control, miR-122 mimic and miR-122 inhibitor groups) and the effect of miR-122 on Maf1 after stroke (control, miR-122 mimic and miR-122 inhibitor groups).

Firstly, 3.5 µl miR-122 negative control (NC), mimic or inhibitor (cat. nos. B04002, B03001 and B02003; Shanghai GenePharma Co., Ltd.) was mixed with 3.5 µl RNAi-mate reagent (cat. no. G04002; Shanghai GenePharma Co., Ltd.) at room temperature for 15 min and stored for later use. After the mice were anesthetized with 400 mg/kg 4% chloral hydrate via intraperitoneal injection, the mixture (7 µl) was injected into the lateral ventricle (over 20 min) at the coordinate (bregma, -2.5 mm; dorsoventral, 1 mm; lateral, 1.5 mm). Subsequently, the wound was sutured and the mice were returned to the cage. At 24 h post-injection, the mouse middle cerebral artery occlusion (MCAO) model was established.

MCAO model. A total of 60 female C57BL/6 mice were selected for this model. The sham operated animals received the same operation as those in the experimental groups except for the coagulation of the blood vessels. The MCAO model (permanent coagulation of the distal middle cerebral artery) is highly reproducible and has a high success rate (the overall mortality is of <5%) (25). Moreover, the relative infarct volume in relation to brain size corresponds to the majority of human strokes (25). Mice were anesthetized with an intraperitoneal injection of 400 mg/kg chloral hydrate. After aseptic preparation of the surgical site, the skin between the ear and the eye was cut under a stereomicroscope (Shanghai Yuyan Instruments Co., Ltd.) using electrocoagulation forceps (Shanghai Yuyan Instruments Co., Ltd.). Once the temporal muscle was removed, a drill (Shanghai Yuyan Instruments Co., Ltd.) with a diameter of 2.5 mm was used to thin out the skull over the middle cerebral artery. The bone was carefully withdrawn to expose the middle cerebral artery, which was then coagulated with electrocoagulation forceps. Subsequently, the wound was sutured and the animal was maintained at 32°C for recovery (25). At 24 h post-model induction, 6 mice in each group were anesthetized with 400 mg/kg chloral hydrate and sacrificed by decapitation. Brain tissues were harvested and sectioned into 2-mm slices. Subsequently, the ischemic site was identified by incubation of the sections with 2% 2,3,5-triphenyl tetrazolium chloride (cat. no. T8170; Beijing Solarbio Science & Technology Co., Ltd.) at 37°C for 15 min in the dark.

Coronal section. Brain tissues were fixed with 4% paraformaldehyde for 6 h at 4°C, the surface liquid was removed by blotting and then the tissues were dehydrated with 15% sucrose solution overnight at 4°C. Subsequently, the tissues were incubated with 30% sucrose solution overnight at 4°C. Coronal sections were prepared into 30-µm sections using a frozen microtome (Leica Microsystems GmbH).

Nissl stain. Sections were washed twice with PBS for 5 sec and stained with Nissl staining solution (cat. no. E607316; Sangon Biotech Co., Ltd.) for 15 min at 25°C. Subsequently, the sections were washed twice with PBS for 5 sec and then washed with 95% ethanol for 5 sec. Stained sections were examined under a Nikon Eclipse Ti inverted fluorescent microscope with a charge-coupled device camera at a magnification of x100. Microscopic images were analyzed with ImageJ (version 1.48; National Institutes of Health).

Prediction of miR-122 target gene. TargetScan (version 7.2; www.targetscan.org/vert_72), miRWalk (version 3; mirwalk.umm.uni-heidelberg.de) and miRDB (version 6.0; mirdb.org) gene prediction software were used to predict the target genes of miR-122. The intersection of the results was identified and used to investigate the association between target genes and ischemic stroke.

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from the cerebral cortex (n=6 per group) using TRIzol® (cat. no. B610409; Sangon Biotech Co., Ltd.). Total RNA was reverse transcribed into cDNA using PrimeScript™ RT reagent kit (cat. no. RR047A; Takara Biotechnology Co., Ltd.) at 37°C for 15 min and 85°C for 5 sec. Subsequently, qPCR was performed using SYBR Green Supermix (cat. no. RR820Q; Takara Biotechnology Co., Ltd.). The following thermocycling conditions were used for qPCR: Denaturation at 95°C for 30 sec; followed by 40 cycles of 95°C for 10 sec and 60°C for 30 sec; and cooling to 4°C. The following primers were used for qPCR: miR-122 (cat. no. ssD809230039; Sangon Biotech Co., Ltd.); Maf1 forward, 5’-GATTGGCCACCTCCAATGATCC-3’ and reverse, 5’-CTCCCTCATCCACTGTCACCC-3’ (Sangon Biotech Co., Ltd.); CEL-39 (cat. no. ssD1083145001; Sangon Biotech Co., Ltd.); and actin-β (ACTB) forward, 5’-GTGCATA TGTTGCTTACAGCTCG-3’ and reverse, 5’-ATGGCCACAG GATTCCTACTAC-3’ (Sangon Biotech Co., Ltd.). miRNA and mRNA expression levels were analyzed using the 2−ΔΔCt method.
method (26) and normalized to the internal reference genes CEL-39 and ACTB, respectively.

**Table I.** Maf1 is predicted to be a target gene for miR-122.

<table>
<thead>
<tr>
<th>RNA</th>
<th>Predicted consequential pairing</th>
</tr>
</thead>
<tbody>
<tr>
<td>mmu-miR-122 3'UTR</td>
<td>GUUUGUGGUAAACAGUGUGAGGU</td>
</tr>
<tr>
<td>mouse-Maf1 5'UTR</td>
<td>UCUUAUGGCGGUCAUUCA</td>
</tr>
<tr>
<td>rat-Maf1 5'UTR</td>
<td>UCUAUUGGGCCUGUACAUCCA</td>
</tr>
<tr>
<td>human-Maf1 5'UTR</td>
<td>UUCUACUGGGCCCUGCACACUCCA</td>
</tr>
</tbody>
</table>

Maf1, repressor of RNA polymerase III transcription MAF1 homolog.

**Construction of vector.** Maf1-3'UTR primers were designed by Sangon Biotech Co., Ltd. (forward, 5'-ATCCAGCTCTGA CCAATC-3' and reverse, 5'-CCAGGTTCATCTAGTCA CAC-3'). The PCR products were cloned into the XhoI and NotI sites of the siCheck vector (Invitrogen; Thermo Fisher Scientific, Inc.) to construct the Maf1-wild-type (WT)-3'UTR vector. The 3'UTR of Maf1 containing the predicted binding site of miR-122 was subjected to site-directed mutation (Sangon Biotech Co., Ltd.) to construct the Maf1-mutant (MUT)-3'UTR vector.

**Dual-luciferase reporter assay.** Cells(293A) were divided into the following four groups: i) Maf1-WT-3'UTR + miR-122 NC (Maf1-WT-3'UTR + NC); ii) Maf1-WT-3'UTR + miR-122 mimic (Maf1-WT-3'UTR + miR-122); iii) Maf1-MUT-3'UTR vector + miR-122 NC (Maf1-MUT-3'UTR + NC); and iv) Maf1-MUT-3'UTR vector + miR-122 mimic (Maf1-MUT-3'UTR + miR-122). 293A cells (Dalian University Microanalysis Laboratory) were plated in 24-well plates at a density of 1x10^5 cells per well in DMEM (Thermo Fisher Scientific, Inc.) containing 10% FBS (Thermo Fisher Scientific, Inc.) and cultured to 90-95% confluence. Subsequently, cells were co-transfected with 50 nM miRNA and 1 µg vector using Lipofectamine® 2000 (cat. no. 11668019; Thermo Fisher Scientific, Inc.). Cells were incubated at 37°C and 5% CO2 and cultured to 90-95% confluence. Subsequently, cells were co-transfected with 50 nM miRNA and 1 µg vector using Lipofectamine® 2000 (cat. no. 11668019; Thermo Fisher Scientific, Inc.). Cells were incubated at 37°C and 5% CO2.
Firefly luciferase activity was normalized to Renilla luciferase activity.

Statistical analysis. Statistical analyses were conducted using SPSS software (version 22.0; IBM Corp.). The data were analyzed using unpaired Student's t-test or one-way ANOVA and Tukey's post-hoc test. Data are expressed as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference. All experiments were performed at least six times.

Results

Establishment of the MCAO model. As presented in Fig. 1A, the middle cerebral artery was exposed in a Y shape. After the middle cerebral artery was coagulated using electrocoagulation forceps, spontaneous recanalization was not observed (Fig. 1B). After MCAO establishment, the infarct brain area was white in color, whereas healthy brain tissues were stained red (Fig. 1C and D).

miR-122 decreases the infarct area. To investigate the relationship between miR-122 and ischemic stroke, the expression level of miR-122 was examined and the effect of miR-122 on the infarct area was evaluated. As presented in Fig. 2A, the expression of miR-122 (sham, 1.00±0.06; MCAO, 1.82±0.10; P<0.05; n=6) was significantly increased after MCAO induction in comparison with sham animals (Fig. 2A). Compared with MCAO model rats treated with control miRNA, the size of the area of infarction was significantly reduced in MCAO model rats that were injected with miR-122 mimic in the lateral ventricle in comparison with control animals. By contrast, the area of infarction increased significantly in comparison with the control following injection of miR-122 inhibitor in the lateral ventricle (control, 2.85±0.27; mimic, 1.19±0.05; inhibitor 6.53±0.17; mimic vs. control and inhibitor vs. control, P<0.05; n=6; Fig. 2B).

miR-122 inhibits Maf1 expression. Subsequently, whether miR-122 inhibited Maf1 expression in vivo was investigated. The results demonstrated that compared with the sham group, the expression of Maf1 in the MCAO group was significantly reduced (sham, 1.00±0.04; MCAO, 0.21±0.04; P<0.01; n=6; Fig. 4A). Furthermore, RT-qPCR results suggested that the expression of Maf1 was significantly reduced after injection of miR-122 mimic in the lateral ventricle. By contrast, the expression of Maf1 increased significantly after the injection of miR-122 inhibitor in the lateral ventricle. The expression levels of miR-122 were as follows: 1.00±0.16, 3.98±0.26 and 0.10±0.04 (mimic vs. control and inhibitor vs. control, P<0.05; n=6; Fig. 4B). Maf1 expression levels were as follows:

Figure 4. miR-122 inhibits the expression of Maf1. (A) Maf1 expression levels in the sham operation and MCAO groups. (B) miR-122 expression in the brain tissue after lateral ventricle injection of miR-122 NC, mimic or inhibitor. (C) Maf1 expression levels in the brain tissue following injection of miR-122 NC, mimic or inhibitor into the lateral ventricle. *P<0.05 vs. sham; †P<0.05 vs. control. miR, microRNA; Maf1, repressor of RNA polymerase III transcription MAF1 homolog; NC, negative control.
Discussion

It has been reported that there is a close relationship between miRNA and ischemic stroke (1,27,28), with the expression of ~20% miRNAs changing during the development and progression of ischemic stroke (29). By regulating the translation process of mRNA, miRNAs can affect protein expression, which subsequently alters biological functions such as axon regeneration, angiogenesis and inflammatory responses (30-33). Several studies have indicated that miR-122 can maintain the caliber and tube shape of blood vessels and reduce neuronal death in an ischemic stroke model (19,34). In addition, miR-122 may serve a pivotal immunomodulatory role in hepatocytes via miR-122-RTKs/STAT3-IRF1-IFNs regulatory circuitry or target TLR4 (35,36). Nerve cells, blood vessels and immunity are critical to the prognosis of infarct area in ischemic stroke (37,38). Therefore, the present study investigated the effect of miR-122 on the outcome of ischemic stroke. Compared with the level in the sham group, the expression of miR-122 increased significantly after MCAO. In addition, increased miR-122 expression effectively reduced the infarct area. By contrast, inhibition of miR-122 expression in brain tissue significantly increased the infarct area, which was consistent with previous studies (19,39). Therefore, the results indicated that miR-122 may exert a protective effect against ischemic stroke by reducing the infarct area.

miRNAs function by regulating the expression of downstream target genes (1); therefore, studying the downstream target genes of miR-122 during the development and progression of ischemic stroke may be important.

Previous studies have indicated that the Maf1 gene is associated with oxygen free radicals, such as H2O2, and the mTOR signaling pathway induced by ischemia (17-18,20). It has also been speculated that the Maf1 gene is associated with ischemic stroke-induced cell death, which further exacerbates brain damage (21-23). The present study demonstrated that the 3’UTR of Maf1 mRNA was a binding site for miR-122 using gene prediction software. Therefore, Maf1 was investigated as a target gene of miR-122. A dual-luciferase reporter assay was performed, which verified that miR-122 bound to the 3’UTR of Maf1. In addition, after MCAO, the expression of miR-122 was increased in comparison with that in a sham model, whereas the expression of Maf1 was reduced, indicating that miR-122 may be negatively associated with Maf1 expression. Therefore, it was hypothesized that the expression of Maf1 may be inhibited by miR-122 after MCAO. Increased miR-122 expression inhibited Maf1 expression and decreased miR-122 expression increased Maf1 expression in vivo. In summary, the present study indicated that miR-122 inhibited Maf1 expression after MCAO. The results of the present study may be beneficial in evaluating the relationship between Maf1 and ischemic stroke and also indicated that miR-122 may be able to improve the outcome of ischemic stroke by regulation of the Maf1 gene. However, the specific role and regulatory mechanism underlying Maf1 and miR-122 activity during the development of ischemic stroke are not completely understood and require further investigation. In contrast to other studies that used male mice, only female mice were used in the present study. Therefore, potential differences in findings in experiments using male mice cannot be ruled out. More studies with male mice may further clarify whether miR-122 promotes the outcome of acute ischemic stroke by reducing the expression of Maf1.

Acknowledgements

Not applicable.

Funding

The present study was funded by the Joint Foundation of Natural Science Foundation of Liaoning Province and Shenyang National Laboratory for Materials Science (grant no. 2019JH3/30100006), the National Natural Science Foundation of China (grant no. 21505013), the Liaoning BaiQianWan Talents Program (grant no. (2019)45) and Dalian Science and Technology Innovation Funds (grant no. 2018J13SN087).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

MW, YB and ML conceived and designed the study, and MW performed the majority of the experiments. MW, XL and YW constructed the MCAO model. YW, JC and JS cultured the cells. MW wrote the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research.

Ethics approval and consent to participate

The present study was approved by the Animal Care Committee of the Xinhua Hospital affiliated to Dalian University and performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References